CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Optimal Cycles of Docetaxel-Based Systemic Chemotherapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC)

Sung Hoon Ahn , Seung Chol Park

Korean J Urol Oncol. 2013;11(2):105-108. Published online 2013 August 30

Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer

Shintaro Narita, Tomonori Habuchi

Hormone Therapy and Castration Resistance of Prostate Cancer. 2018;357-368

Link1

Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer

S.C.H. Park, L.J. Whan, R.J. Sik

Actas Urológicas Españolas (English Edition). 2012;36(7):425-430

Link1 Link2

Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy

Yuh-Shyan Tsai, Tzong-Shin Tzai

Urological Science. 2015;26(4):277

Link1 Link2

Systemic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Dong Hoon Lee, Sung-Woo Park

Management of Advanced Prostate Cancer. 2018;167-173

Link1

S52 EFFICACY OF DOCETAXEL-BASED CHEMOTHERAPY IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

A. Garayev, N. Mangir, I. Tinay, L. Turkeri

European Urology Supplements. 2012;11(4):145

Link1 Link2

The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer

Jatinder Goyal, Philipp Nuhn, Peng Huang, Prachi Tyagi, Daniel Oh, Michael A. Carducci, Mario A. Eisenberger, Emmanuel S. Antonarakis

BJU International. 2012;110(11b):E575-E582

Link1 Link2

Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy

Betsan M. Thomas, Christian Smith, Jessica Evans, Michael R. Button, Satish Kumar, Nachi Palaniappan, John Staffurth, Jacob S. Tanguay, Jason F. Lester

Medical Oncology. 2013;30(4):

Link1

Link2 Link3

Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer

A J Armstrong, D J George

Prostate Cancer and Prostatic Diseases. 2010;13(2):108-116

Link1

Link2 Link3

581 RE-TREATMENT WITH DOCETAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)

Angela Gernone, Giuseppe Troccoli, Vincenzo Pagliarulo, Arcangelo Pagliarulo

Journal of Urology. 2010;183(4S):

Link1 Link2

896 RE-TREATMENT WITH DOCETAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)

A.G. Gernone, G.T. Troccoli, V.P. Pagliarulo, A.P. Pagliarulo

European Urology Supplements. 2010;9(2):283

Link1 Link2